Royal London Hospital

Running trials

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

  NCT07683325· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

  NCT07416526· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  NCT07533006· Phase 2· Eli Lilly and Company· Source

• Recruiting

  PS-002 for the Treatment of IgA Nephropathy in Adults

  NCT07182227· Phase 1/2· Purespring Therapeutics Limited· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· CSL Behring· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

  NCT06721013· Phase 1/2· Eli Lilly and Company· Source

• Recruiting

  The Barts Charity Children's Environmental Health Clinic

  NCT06447974· Queen Mary University of London· Source

• Recruiting

  Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07013916· Queen Mary University of London· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

  NCT06923111· Nova Laboratories Limited· Source

• Active, not recruiting

  Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

  NCT06956235· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Ambroxol to Slow Progression in Parkinson Disease

  NCT05778617· Phase 3· University College, London· Source

• Active, not recruiting

  A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

  NCT06780449· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  NCT06379789· Phase 1/2· Regeneron Pharmaceuticals· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

  NCT06455202· Phase 3· Celldex Therapeutics· Source

• Recruiting

  Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

  NCT06277037· Arbutus Biopharma Corporation· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

  NCT05781113· Celestra Health Systems· Source

• Active, not recruiting

  A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

  NCT05631093· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

  NCT05630755· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

  NCT05418010· Phase 2· Queen Mary University of London· Source

• Recruiting

  Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

  NCT04939935· Phase 3· The University of Queensland· Source

• Active, not recruiting

  A Study of Rusfertide in Adults With Polycythemia Vera (PV)

  NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source

• Active, not recruiting

  LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment

  NCT04999423· Microvention-Terumo, Inc.· Source

• Active, not recruiting

  A Long-term Extension Study of Ustekinumab in Pediatric Participants

  NCT05092269· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

  NCT04936620· St George's, University of London· Source

• Active, not recruiting

  ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

  NCT04695080· Phase 2/3· Queen Mary University of London· Source

• Recruiting

  Electroporation for Cancer Treatment Real World Registry

  NCT04929912· Mirai Medical· Source

• Recruiting

  A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

  NCT04844606· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Atrasentan in Patients With IgA Nephropathy

  NCT04573478· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)

  NCT05649384· University Hospital, Basel, Switzerland· Source

• Active, not recruiting

  UNICORNS: Uveitis in Childhood Prospective National Cohort Study

  NCT05385757· Institute of Child Health· Source

• Recruiting

  Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

  NCT04302870· Phase 2/3· University of Edinburgh· Source

• Active, not recruiting

  Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers

  NCT04449406· Queen Mary University of London· Source

Showing 50 of 57.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease5 recruiting
• Haemophilia3 recruiting
• Ulcerative colitis3 recruiting
• Epilepsy2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Hepatitis B2 recruiting
• Multiple sclerosis2 recruiting
• Obesity2 recruiting
• Parkinson disease2 recruiting
• Sickle cell disease2 recruiting
• Alopecia areata1 recruiting
• ALS (motor neurone disease)1 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Hepatitis C1 recruiting
• HIV1 recruiting
• IgA nephropathy1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lung cancer1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Spinal cord injury1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study Evaluating the Use of ResAppDx v2.0 as an Aid to Diagnose Respiratory Disease in Paediatric Patients in an Emergency Department

  NCT06156436· ResApp Health Limited· Source

• Completed

  A Study Evaluating the Use of ResAppDx v2.0 as an Aid to Diagnose Respiratory Disease in Adolescent and Adult Patients in an Emergency Department

  NCT06156462· ResApp Health Limited· Source

• Completed

  An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

  NCT06126146· AbbVie· Source

• Completed

  A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

  NCT05936151· Phase 2· Eli Lilly and Company· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Multi-Nutrient Supplementation as a Therapeutic Intervention in Ischaemic Stroke

  NCT05474105· Barts & The London NHS Trust· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial

  NCT05482698· Phase 2· MC2 Therapeutics· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Completed

  Improving AF Detection in Cryptogenic Stroke

  NCT05007847· Barts & The London NHS Trust· Source

• Completed

  Bacterial Lysate In Preventing Asthma

  NCT05064631· Phase 2· Queen Mary University of London· Source

• Completed

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

  NCT04779307· Phase 3· Takeda· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT04673357· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT04630028· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

  NCT04166773· Phase 2· Eli Lilly and Company· Source

• Completed

  Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

  NCT04029480· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients

  NCT07022626· Barts & The London NHS Trust· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Hoffmann-La Roche· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Completed

  Gene Therapy Study in Severe Haemophilia A Patients (270-201)

  NCT02576795· Phase 1/2· BioMarin Pharmaceutical· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple sclerosis33 works · 6 trials